These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 30616755)

  • 1. Glioblastoma Therapy in the Age of Molecular Medicine.
    Geraldo LHM; Garcia C; da Fonseca ACC; Dubois LGF; de Sampaio E Spohr TCL; Matias D; de Camargo Magalhães ES; do Amaral RF; da Rosa BG; Grimaldi I; Leser FS; Janeiro JM; Macharia L; Wanjiru C; Pereira CM; Moura-Neto V; Freitas C; Lima FRS
    Trends Cancer; 2019 Jan; 5(1):46-65. PubMed ID: 30616755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Immunotherapeutic Approaches for Glioblastoma.
    Vázquez Cervantes GI; González Esquivel DF; Gómez-Manzo S; Pineda B; Pérez de la Cruz V
    J Immunol Res; 2021; 2021():3412906. PubMed ID: 34557553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
    Choi BD; Maus MV; June CH; Sampson JH
    Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy.
    Ishikawa E; Miyazaki T; Takano S; Akutsu H
    Brain Tumor Pathol; 2021 Jul; 38(3):149-155. PubMed ID: 33977360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma.
    Tu S; Lin X; Qiu J; Zhou J; Wang H; Hu S; Yao Y; Wang Y; Deng Y; Zhou Y; Shao A
    Front Immunol; 2021; 12():650105. PubMed ID: 34394072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab and Glioblastoma: Past, Present, and Future Directions.
    Kim MM; Umemura Y; Leung D
    Cancer J; 2018; 24(4):180-186. PubMed ID: 30119081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
    Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
    Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial: The State-of-Art in Immuno-Oncology, What to Do With Glioblastoma?
    Cui X; Wang Q; Kang C
    Front Immunol; 2021; 12():788733. PubMed ID: 34777399
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapies for the Treatment of Glioblastoma in Adults.
    Chuang DF; Lin X
    Curr Oncol Rep; 2019 May; 21(7):61. PubMed ID: 31102038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma.
    Zhang H; Zhou Y; Cui B; Liu Z; Shen H
    Biomed Pharmacother; 2020 Jun; 126():110086. PubMed ID: 32172060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
    Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
    Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
    [No Abstract]   [Full Text] [Related]  

  • 16. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards Immunotherapy for Pediatric Brain Tumors.
    Wang SS; Bandopadhayay P; Jenkins MR
    Trends Immunol; 2019 Aug; 40(8):748-761. PubMed ID: 31229353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
    Datta M; Coussens LM; Nishikawa H; Hodi FS; Jain RK
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():165-174. PubMed ID: 31099649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
    Bambury RM; Morris PG
    Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape.
    Mohme M; Maire CL; Schliffke S; Joosse SA; Alawi M; Matschke J; Schüller U; Dierlamm J; Martens T; Pantel K; Riethdorf S; Lamszus K; Westphal M
    Acta Neuropathol Commun; 2020 Mar; 8(1):28. PubMed ID: 32151286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.